Ghiringhelli François
Université de Bourgogne Franche-Comté, 21000 Dijon, France; Centre Georges-François-Leclerc, département d'oncologie médicale, 1, rue du Professeur-Marion, 21000 Dijon, France; Inserm LNC U1231, 21000 Dijon, France.
Bull Cancer. 2018 Dec;105 Suppl 1:S101-S112. doi: 10.1016/S0007-4551(18)30395-3.
Recent advances in immuno-oncology with the development of anti-PD1/PD-L1 antibodies are revolutionizing oncological management. Immuno-oncology I currently developing in most histological types of cancer. However, the rate of success of anti-PD1/PD-L1 antibodies in monotherapy is limited by a limited to a subpopulation of patients accounting for about 25-30 % of patients in most indications. The development of new strategies is based on this observation with the aim to predict response or enhancing response rate. Thus, we note the development of different strategies aimed at better selecting patients or combining inhibitory checkpoints with other therapies in order to increase their effectiveness. This review will study therapeutic test strategies to validate these new associations.
随着抗PD1/PD-L1抗体的发展，免疫肿瘤学的最新进展正在彻底改变肿瘤学治疗方式。免疫肿瘤学目前正在大多数组织学类型的癌症中进行研发。然而，抗PD1/PD-L1抗体单药治疗的成功率有限，在大多数适应症中，仅约25%-30%的患者亚群有反应。基于这一观察结果，新策略的开发旨在预测反应或提高反应率。因此，我们注意到正在开发不同的策略，旨在更好地选择患者或将抑制性检查点与其他疗法联合使用，以提高其有效性。本综述将研究治疗性试验策略，以验证这些新的联合疗法。
